Abstract: With the pharmaceutical industry facing irreversible losses of market capitalization, patent protection on blockbuster drugs, and an industry-wide, mid-stage R&D pipeline gap, this paper from Deloitte argues that it is high time for a reassessment of Large Pharma's business model and the reinvention of innovation in the industry.

 Published: November 21, 2008

Author: Deloitte

Link: Deloitte